The Europe dry eye syndrome market size reached US$ 757.2 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 1,153.5 Million by 2032, exhibiting a growth rate (CAGR) of 4.6% during 2024-2032.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2023
|
Forecast Years
|
2024-2032
|
Historical Years
|
2018-2023
|
Market Size in 2023 | US$ 757.2 Million |
Market Forecast in 2032 | US$ 1,153.5 Million |
Market Growth Rate (2024-2032) | 4.6% |
Dry eye syndrome, or keratoconjunctivitis sicca (KCS), is a medical disorder that occurs due to the lack of moisture or lubrication on the surface of the eye. It is a chronic ailment characterized by various symptoms, such as redness, discomfort, aching and burning sensations and photophobia. Dry eye syndrome is also caused due to multiple factors, such as allergies, laser surgeries, extensive computer usage, medication, menopause, deficiency of vitamin A and other autoimmune diseases. It can be treated through administering artificial tears, medications, lacrimal plugs and surgeries. Dry eye syndrome can be prevented by avoiding smoking and wearing wraparound sunglasses or other protective eyewear.
The growth in the Europe dry eye syndrome market can be attributed to the rising geriatric population prone to chronic eye-related diseases. Dry eye syndrome is also associated with various other medical conditions, such as Sjogren's syndrome, rheumatoid arthritis, lupus, scleroderma, sarcoidosis, thyroid disorders and diabetes, which is highly prevalent among elderly patients. In addition to this, sedentary lifestyles and a lack of physical activities of the masses are resulting in the increasing oxidative stress and reducing mucin expression in the eyes, which is also impacting the occurrence of dry eye syndrome. Consequently, patients and healthcare providers are widely adopting corticosteroids drugs for the effective treatment of dry eye syndrome. Corticosteroids are anti-inflammatory drugs that offer short-term efficacy and are prescribed for acute cases of dry eye diseases. Other factors, including significant improvements in the diagnostic technologies, along with rising healthcare expenditure capacities of the consumers and the increasing utilization of smartphones, laptops and television among the masses leading to prolonged and excessive screen time, are creating a positive outlook for the market.
IMARC Group provides an analysis of the key trends in each segment of the Europe dry eye syndrome market report, along with forecasts at the regional and country levels from 2024-2032. Our report has categorized the market based on disease type, drug type, product and distribution channel.
Breakup by Disease Type:
Breakup by Drug Type:
Breakup by Product:
Breakup by Distribution Channel:
Breakup by Country:
The competitive landscape of the industry has also been examined along with the profiles of the key players.
Report Features | Details |
---|---|
Base Year of the Analysis | 2023 |
Historical Period | 2018-2023 |
Forecast Period | 2024-2032 |
Units | US$ Million |
Segment Coverage | Disease Type, Drug Type, Product, Distribution Channel, Country |
Countries Covered | Germany, France, United Kingdom, Italy, Spain, Others |
Customization Scope | 10% Free Customization |
Report Price and Purchase Option | Single User License: US$ 3699 Five User License: US$ 4699 Corporate License: US$ 5699 |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |